Loading
HKSEHealthcareBiotechnology
Latest quote
HK$1.12
HK$0.00 · 0.00%
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Latest quote
HK$1.12
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Day range
Current HK$1.12
52-week range
Current HK$1.12
Regular session · HKT · Market data may be delayed.
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Day range
Current HK$1.12
52-week range
Current HK$1.12
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 2.03M CNY | 1.37M CNY | 4.03M CNY | 26.66M CNY |
| Cost of goods sold | 26.64M CNY | 1.48M CNY | 943K CNY | — | — |
| Gross profit | −26.64M CNY | 543K CNY | 422K CNY | 4.03M CNY | 26.66M CNY |
| Research and development | 79.51M CNY | 94.75M CNY | 135.41M CNY | 180.37M CNY | 199.11M CNY |
| Selling, general, and administrative | 46.38M CNY | 67.72M CNY | 97.62M CNY | 82.59M CNY | 133.4M CNY |
| Operating expenses | 98.06M CNY | 161.9M CNY | 230M CNY | 262.96M CNY | 331.77M CNY |
| Interest income | 3.62M CNY | 5.88M CNY | 6.18M CNY | 4.62M CNY | 16.73M CNY |
| Interest expense | 5.38M CNY | 8.66M CNY | 6.58M CNY | — | 5.82M CNY |
| Depreciation and amortization | 27.35M CNY | 19.13M CNY | 36.06M CNY | 14.63M CNY | 9.43M CNY |
| Operating income | −124.7M CNY | −161.36M CNY | −229.58M CNY | −258.93M CNY | −305.86M CNY |
| Net income | −102.27M CNY | −185.14M CNY | −243.11M CNY | −284.16M CNY | −288.19M CNY |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
